Sprint Bioscience AB (SPRINT) fair value: what the stock is really worth
As of Nov 13, 2026: fair value (intrinsic value) of Sprint Bioscience AB stock SEK 9.87, price SEK 3.87, upside +155.0%, quality 69 out of 100. Rating: strongly undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.
How to read this chart
60‑month range kr 0.4090 – kr 4.60 · fair‑value band kr 5.93 – kr 19.65 · the kr 3.87 price screens below the kr 9.87 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.
Follow Sprint Bioscience in your weekly email
Every Wednesday you see whether Sprint Bioscience is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden.
Show moreShow less
The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer.
It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash.
It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases and evaluation of the STK25 program. The company was incorporated in 2009 and is based in Huddinge, Sweden.
Stock analysis
Sprint Bioscience AB (SPRINT) currently trades at kr 3.87, while our model-based Fair Value estimate is kr 9.87, implying the stock looks roughly 61% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of kr 40.39 per share, and 22 of the 24 models we run sit above the kr 3.87 price.
Bear case: the Asset-Based group reads lowest at kr 1.09, and 2 of the 24 models stay below the price. Data coverage for this calculation is low.
Scenario range: kr 5.93 (bear) to kr 19.65 (bull), the price of kr 3.87 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 69/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Sprint Bioscience AB reported revenue of 167M SEK in FY2025 versus 35.1M SEK in FY2021, a compound +47.7%/yr. Reported net income was 91.7M SEK in FY2025.
Key figures
Market cap 408M SEK (≈ $40.5M) Micro · P/E ratio 5.2 · P/S ratio 2.93 · EPS (TTM) kr 0.7500 · Net margin 54.3% · Return on equity 145% · Return on assets (EBIT) −34.4% (5-year average) · Operating margin 56.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 90 out of 100 (low confidence).
What moves the price
The share trades about 14% below its 52-week high and 505% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 155%, SPRINT screens cheaper than that median.
Fair Value models
Bearkr 5.93Fair Value kr 9.87Bullkr 19.65
Price kr 3.87 · Upside +155.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (kr 0.6534 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCFkr 14.62kr 21.86kr 44.4474
EPVkr 8.75kr 9.94kr 10.9774
Growth DCFkr 13.80kr 25.19kr 43.5373
All 24 models by family
DCF Models
FCF DCFkr 14.62kr 21.86kr 44.4474
Owner Earningskr 13.73kr 28.97kr 59.7869
5Y Revenue Exitkr 7.67kr 11.04kr 17.9869
5Y EBITDA Exitkr 12.27kr 20.33kr 36.1370
5Y P/E Exitkr 15.63kr 33.65kr 58.2565
10Y Revenue Exitkr 9.72kr 16.74kr 20.2365
10Y EBITDA Exitkr 13.14kr 26.41kr 49.1263
10Y P/E Exitkr 15.54kr 33.49kr 63.0558
Earnings-Based
Graham-Doddkr 5.91kr 41.23kr 57.8661
Lynch FVkr 21.30kr 30.43kr 39.5659
PEG = 1.0kr 21.30kr 30.43kr 39.5655
EPVkr 8.75kr 9.94kr 10.9774
Multiples
P/E Multiplekr 14.35kr 19.13kr 23.9163
P/S Multiplekr 4.16kr 5.55kr 6.9358
P/B Multiplekr 0.9500kr 1.27kr 1.5955
EV/EBITkr 12.96kr 16.88kr 20.8066
EV/EBITDAkr 10.99kr 14.26kr 17.5267
EV/Revenuekr 4.53kr 5.95kr 7.3854
Asset-Based
NCAV (Graham)kr 0.7200kr 1.09kr 1.3754
Growth DCF
Growth DCFkr 13.80kr 25.19kr 43.5373
Rev-Margin DCFkr 8.26kr 12.48kr 20.8769
Economic Profit
Residual Incomekr 4.27kr 7.78kr 23.9756
ROIC Compounderkr 8.75kr 9.94kr 10.9770
Growth Earnings
Growth-Adj P/Ekr 28.27kr 40.39kr 52.5165
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.92/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+154.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+58.2%
Start year 2020 (pandemic). Over 10 years: +36.0% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+35.5%
’13
’14
’15
’16
’17
’18
’19
’20
’21
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−223.1% (2020) → 58.2% (2025)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−23.1%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Sweden: IMF forecast 2.0% a year to 2030, 2.9% from 2016 to 2025) that is about −24.6% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks
Beats the industry median on 10/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score69 · Top 25%
Fair Value upside+155.0% · Top 25%
Profitability
Return on equity (12 months)145.0% · Top 25%
Return on assets67.1% · Top 25%
Net margin (12 months)54.3% · Top 25%
Operating margin (12 months)56.6% · Top 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Sprint Bioscience AB Fair Value". https://www.fairvalue-calculator.com/stock/SPRINT
Frequently asked questions
Is Sprint Bioscience AB (SPRINT) overvalued or undervalued?
As of Nov 14, 2026, our model estimates a fair value of kr 9.87 versus a price of kr 3.87, about +155% upside (undervalued).
What is the fair value of SPRINT?
Our model-based fair value for Sprint Bioscience AB is kr 9.87 (as of Nov 14, 2026), built from audited fundamentals. The current price: kr 3.87.
What is the quality score of SPRINT?
Sprint Bioscience AB has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sprint Bioscience AB (SPRINT)?
Our model-based price target is the fair value of kr 9.87 (as of Nov 14, 2026) from 24 valuation models. Cautious scenario kr 5.93, optimistic scenario kr 19.65. It is a calculation from audited fundamentals, not an analyst target.
What is the Sprint Bioscience AB stock forecast for 2026?
Our models put fair value at kr 9.87, about +155% upside versus a price of kr 3.87 (undervalued). Cautious scenario kr 5.93, optimistic scenario kr 19.65. The calculation is refreshed regularly with new filings.
What is the revenue of Sprint Bioscience AB (SPRINT)?
Sprint Bioscience AB reported trailing-twelve-month revenue of about 139M SEK (latest available figure, as of Nov 14, 2026).
What growth is priced into Sprint Bioscience AB (SPRINT)?
For today's price to be fair in a discounted-cash-flow model, Sprint Bioscience AB would have to grow free cash flow by -23.1 % per year for five years (discount rate 9.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +58.2 % per year. As of Nov 14, 2026.
What discount rate (WACC) does the fair value of SPRINT use?
Our models discount Sprint Bioscience AB at 9.5 %: a base by market capitalisation (nano), country premium for Sweden. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Sprint Bioscience AB that is -23.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.5 %) and the same formula as our fair value.
How much growth has Sprint Bioscience AB (SPRINT) delivered so far?
Over the past 5 years revenue at Sprint Bioscience AB grew +58.2 % a year. The price currently implies free-cash-flow growth of -23.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Sprint Bioscience AB (SPRINT) growing?
The median revenue growth in the sector is +5.8 % a year. That is the yardstick for the growth priced into Sprint Bioscience AB (-23.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Sprint Bioscience AB (SPRINT)?
The free-cash-flow yield on the price is 20.43 %: that much free cash flow Sprint Bioscience AB produces per unit of market value. When it exceeds the discount rate of our models (9.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Sprint Bioscience AB (SPRINT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sprint Bioscience AB it is kr 9.87 per share (as of Nov 14, 2026), against a price of kr 3.87. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Sprint Bioscience AB stock overvalued or undervalued in 2026?
As of Nov 14, 2026, SPRINT trades below its calculated fair value: price kr 3.87, fair value kr 9.87, a gap of about +155% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SPRINT?
No. The price is what the market pays today (kr 3.87); the fair value is what the company's own numbers justify (kr 9.87). For Sprint Bioscience AB the two are kr 6.00 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sprint Bioscience AB worth?
The market values Sprint Bioscience AB at about 408M SEK (market capitalisation, as of Nov 14, 2026). Per share that is kr 3.87; our models calculate a fair value of kr 9.87 per share.
What do the bullish and bearish scenarios say about SPRINT?
Our models span a range for Sprint Bioscience AB: cautious scenario kr 5.93, base kr 9.87, optimistic kr 19.65 per share (as of Nov 14, 2026, price kr 3.87). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SPRINT?
Sprint Bioscience AB trades at a price-to-earnings ratio of 5.2 (as of Nov 14, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 9.87 is built from several models across several years. Other multiples: P/B 3.4, P/S 2.9, EV/EBITDA 3.5.
How solid is the balance sheet of Sprint Bioscience AB (SPRINT)?
Balance-sheet figures for Sprint Bioscience AB (as of Nov 14, 2026): return on equity 145.0%. They feed the Quality Score of 69/100, which measures business quality independently of the share price.
How far is SPRINT from its 52-week high?
Sprint Bioscience AB trades at kr 3.87, about 14% below its 52-week high of kr 4.49 and 505% above the low of kr 0.6400 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of kr 9.87 is for.
Which stocks are comparable to Sprint Bioscience AB?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sprint Bioscience AB stock attractive at the current price?
The data as of Nov 14, 2026: price kr 3.87, calculated fair value kr 9.87 (+155%), Quality Score 69/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SPRINT calculated?
We run Sprint Bioscience AB through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of kr 9.87 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9% above its aggregate fair value. Sprint Bioscience AB currently trades 61% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sprint Bioscience AB (SPRINT)?
The closing price on Nov 13, 2026 was kr 3.87. Our model-based fair value is kr 9.87, about +155% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sprint Bioscience AB right now?
The price is below even our cautious bear case (kr 5.93). The market is more pessimistic than our downside scenario. The model range is unusually wide (kr 5.93 to kr 19.65). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (69/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Sprint Bioscience AB
How large is the market capitalisation of Sprint Bioscience AB (SPRINT)?
The market capitalisation of Sprint Bioscience AB is 408M SEK (≈ $40.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sprint Bioscience AB (SPRINT)?
The price-to-sales ratio of Sprint Bioscience AB is 2.93 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sprint Bioscience AB (SPRINT)?
Earnings per share at Sprint Bioscience AB are kr 0.7500 (price ÷ EPS = P/E 5.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Sprint Bioscience AB (SPRINT)?
The net margin of Sprint Bioscience AB is 54.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sprint Bioscience AB (SPRINT)?
The return on equity (ROE) of Sprint Bioscience AB is 145% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sprint Bioscience AB (SPRINT)?
On an EBIT basis the return on assets of Sprint Bioscience AB is −34.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sprint Bioscience AB (SPRINT)?
The operating margin of Sprint Bioscience AB is 56.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much net cash does Sprint Bioscience AB (SPRINT) hold?
Sprint Bioscience AB holds more cash than debt, 127M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Sprint Bioscience AB in the live analysis
One click puts Sprint Bioscience AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 14, 2026